Oddo BHF - Credit Morning 11/29/2016

Report

Oddo BHF

Carole Braudeau

Credit Morning 11/29/2016

SGL Carbon SE raises capital to strengthen the capital structure.>

29/11/2016 11 EN

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Carole Braudeau

Other Reports from Oddo BHF

Bruno Cavalier

Bruno Cavalier

Trois questions autour de la Fed (taux, bilan, Powell)

Tiraillée entre des forces contraires, les unes poussant au freinage de la croissance, les autres à la hausse des prix, la Fed ne sait pas quel parti prendre. La distribution du FOMC sur l’orientation des taux directeurs est devenue presque bimodale (c’est inédit). Un camp est opposé à toute baisse des taux en 2025, l’autre est prêt à reprendre l’assouplissement. Le débat ne sera pas tranché avant la fin de l’été au mieux, en espérant que d’ici là on y voit plus clair sur le pricing power des entreprises et la situation du marché du travail. Plutôt que de sans cesse pressurer Powell pour obten...

4m 4m 1 FR

Markus Schmitt

Markus Schmitt

Cheplapharm Arzneimittel : Chepla upsizes and prices new 2031 SSNs: we adopt a Neutral recommendation

Cheplapharm (CHEPDE, B3/B) priced the new 2031 SSNs (refinancing the 2027 SSNs) and upsized the issuance to EUR 750m from EUR 500m. The overfunding bolsters liquidity (think about the 2028 maturities) and/or is potentially used when Chepla will be restarting the M&A strategy at one point, while meanwhile accepting the negative carry on the overfunding. We required a minimum yield of 7.5% for the new 2031 SSNs. The final yield of 7.125% is below our requirement. The yield of the existing 2030 fixed SSNs dropped also already after we adopted a Buy recommendation the other day. While there is sti...

1h / 16m 1h / 16m 1 EN

Markus Schmitt

Markus Schmitt

Cheplapharm Arzneimittel : Chepla upsizes and prices new 2031 SSNs: we adopt a Neutral recommendation

1h / 22m 1h / 22m 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Credit Morning 11/29/2016

Trois questions autour de la Fed (taux, bilan, Powell)

Cheplapharm Arzneimittel : Chepla upsizes and prices new 2031 SSNs: we adopt a Neutral recommendation

Cheplapharm Arzneimittel : Chepla upsizes and prices new 2031 SSNs: we adopt a Neutral recommendation

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe